(MENAFN) Irish-listed Amryt Pharma, which is focused on finding treatments for rare and orphan diseases, has signed a distribution agreement for the company's Lojuxta (lomitapide) product covering Lebanon, Jordan and Syria.
The agreement is with Pharaon Healthcare-Droguerie Mercury, one of the leading full-service distributors in the region, the company said.
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia ("HoFH"), a rare, life-limiting disease, which damages the body's ability to remove bad cholesterol from the blood.
The disease typically results in extremely high bad cholesterol levels in blood, leading to aggressive and premature narrowing and blocking of blood vessels.
"This is Amryt's fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria," Dr. Joe Wiley, chief executive officer of Amryt, said.
"Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians' requests regarding their patients suffering with HoFH."
Amryt estimates that there are approximately 40 patients with HoFH in the countries covered by this agreement, with Lebanon in particular having a pronounced "founder effect" and therefore materially higher prevalence of HoFH, according to the company.
MENAFN0603201800450000ID1096549959
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.